M&A Deal Summary |
|
|---|---|
| Date | 2023-12-18 |
| Target | Point Biopharma Global |
| Sector | Life Science |
| Buyer(s) | Lilly |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1876 |
| Sector | Life Science |
| Employees | 43,000 |
| Revenue | 34.1B USD (2023) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 33 of 34 |
| Sector (Life Science) | 26 of 27 |
| Type (Add-on Acquisition) | 26 of 27 |
| State (Indiana) | 1 of 1 |
| Country (United States) | 28 of 29 |
| Year (2023) | 5 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-10-18 |
Mablink
Lyon, France Mablink is a biotechnology company developing the next generation of an emerging class of cancer drugs called antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink™, enables the design of homogeneous, plasma- stable, next generation ADCs with high DAR (drug-to-antibody ratio) while maintaining excellent pharmacological properties and tolerability. Mablink was founded in 2018 and is based in Lyon, France. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-07-08 |
Morphic
Waltham, Massachusetts, United States Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for treating serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. The company is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform that leverages Morphic's unique understanding of integrin structure and biology. Morphic is based in Waltham, Massachusetts. |
Buy | - |
